DAYGLIPTION

A novel dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

Signigicantly reduced the 24hrs mean sensor glucose levels & AUC180

Effectiv and consistent glycemic control with a good tolerability profile, including no severe hypolycemia and weight gain